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Background. Tacrolimus (TAC) and mycophenolate 
mofetil (MMF) are currently approved immunosup-
pressants for prevention of rejection in liver trans-
plantation (LTx). They have different modes of action 
and toxicity profiles, but the efficacy and safety of 
MMF in primary liver transplantation with TAC has 
not been determined. 
Methods. An Institutional Review Board-approved, 
open-label, single-center, prospective randomized 
trial was initiated to study the efficacy and toxicity of 
TAC and steroids (double-drug therapy (D» versus 
TAC, steroids, and MMF (triple-drug therapy (T» in 
primary adult LTx recipients. Both groups of patients 
were started on the same doses of TAC and steroids. 
Patients randomized to T also received 1 gm MMF 
twice a day. 
Results. Between August 1995 and May 1998, 350 pa-
tients were enrolled at a single center-175 in the D and 
175 in the T groups. All patients were followed until 
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May 1998, with a mean follow-up of 33.8±9.1 months. 
Using an intention-to-treat analysis, the 1-, 2-, 3-, and 
4-year patient survival was 85.1%, 81.6%, 78.6%, and 
75.8%, respectively, for D and 87.4%, 85.4%, 81.3%, and 
79.9%, respectively, for T. The 4-year graft survival 
was 70% for D and 72.1% for T. Although the rate of 
acute rejection in the first 3 months was significantly 
lower for T than for D (28% for triple vs. 38.9% for 
double, P=0.03), the overall rate of rejection for T at 
the end of 1 year was not significantly lower than for 
the D (38.9% triple vs. 45.2% double). The median time 
to the first episode of rejection was 14 days for D 
versus 24 days for T (P=0.OO8). During the study pe-
riod, 38 of 175 patients in D received MMF to control 
ongoing acute rejection, nephrotoxicity, and/or neuro-
toxicity. On the other hand, 103 patients in the T dis-
continued MMF for infection, myelosuppression, 
and/or gastrointestinal disturbances. The need for cor-
ticosteroids was less after 6 months for T and the peri-
operative need for dialysis was lower with use ofMMF. 
Conclusion. This imal report confirms similar pa-
tient survival and graft survival up to 4 years with a 
trend towards fewer episodes of rejection, lower need 
for steroids, and better perioperative renal function. 
However, the complex nature of LTx patients and 
their posttransplantation course prevents the routine 
application of MMF. 
INTRODUCTION 
The FDA approved tacrolimus (TAC) in 1993 for liver 
transplantation (LTx), whereas the FDA approved mycophe-
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nolate mofetil (MMF) in 2000 for use in L Tx. Approval for 
TAC was based upon randomized trials ofTAC and steroids 
versus cyclosporine-based immunosuppression, in which 
TAC demonstrated significantly lower rates and severity of 
rejection (1,2). MMF approval for LTx was based on compar-
ison with azathioprine (AZA) in conjunction with a cyclospor-
ine (CsA)-based immunosuppressive regimen (3). Each drug 
has a different mode of action and different side effects. TAC 
acts to block the production of interleukin (IL)-2, which in 
turn prevents the proliferation ofT helper lymphocytes, thus 
preventing allogeneic responses in the host (4). The main side 
effects of TAC were delineated in early clinical trials and 
include neurotoxicity and nephrotoxicity (5, 6). MMF inter-
feres with inosine monophosphate dehydrogenase, a key en-
zyme involved with de novo synthesis in lymphocytes (7). The 
main side effects of MMF are gastrointestinal and bone mar-
row suppression (8, 9). 
Until the initiation of the current study, no prospective 
trials combining these two agents as primary immunosup-
pression in LTx had been performed. The aim of the present 
study was to compare the combination of TAC and steroids 
(double-drug therapy (D) group), versus TAC, steroids, and 
MMF (triple-drug therapy (T) group) in primary adult (age 
> 18 years) LTx recipients. The endpoint of the study in-
cluded patient and graft survival, incidence and severity of 
rejection, incidence and nature of infection, and nature and 
severity of side effects. In November 1990, we published an 
interim report on the first 200 patients with a mean follow-up 
of 12.7±0.4 months (10). The current report represents the 
entire 350-patient enrollment. with long-term follow-up. 
MATERIALS AND METHODS 
The Institutional Review Board of the University of Pittsburgh 
approved the following protocol in August 1995. Patients were ran-
domized in l:l-ratio computerized sequential draw assignments us-
ing a variable block randomization procedure (11). 
Patient Characteristics 
The present report consists of the entire study population of 350 
consenting adult patients enrolled between August 1995 and May 
1998. All patients were followed until January 2000, with a mean 
follow-up of 33.8:+:9.1 months (range 20-53). The patient and donor 
characteristics for both Groups are shown in Table 1. The indications 
for LTx are shown in Table 2. 
Immunosuppression Protocol 
Patients in both groups received TAC at 0.03 to 0.05 mg/kg/day 
intravenously as a starting dose, commencing immediately after 
reperfusion of the liver allograft. Subsequent adjustments in the 
TAC dosage were made to achieve a whole blood TAC concentration 
of 15 to 20 ng/ml when on intravenous therapy and a trough level of 
12 to 15 ng/ml when on oral TAC therapy during the first postoper-
ative month. The target trough levels were 10 to 15 ng/ml beyond the 
second postoperative month. All patients also received 1 g methyl-
prednisolone upon reperfusion of the liver and a 6-day methylpred-
nisolone taper thereafter, starting at 200 mg/day and ending at a 
baseline dose of 20 mg/day. Subsequent adjustment in maintenance 
prednisone was dependent upon the patient's clinical course. Pa-
tients who experienced an acute rejection episode were initially 
treated with a single I-g bolus of methylprednisolone and optimiza-
tion of TAC levels. If the liver function tests did not improve within 
24 hr after the steroid bolus, a gradual steroid taper was introduced, 
starting at 200 mg of methylprednisolone and tapering by 40 mg/day 
to 20 mg prednisone over the ensuing 5 days. Patients who failed 
TABLE 1. Patient characteristics 
Group Double Triple 
n(%) n(%) 
Recipient 
Male 111(63.4) 91 (52.0) 
Female 64 (36.6) 84 (48.0) 
Mean age (years) 52.4:+:1O.S 52.3:+: 11.9 
Range 17.6-72 IS.3-73 
UNOS 
Home bound 60 (34.3) 66 (37.7) 
Hospital bound 38 (21.7) 33 (18.9) 
ICU bound 77 (44.0) 76 (43.4) 
Donor 
Mean age (yrs) 39:+:17 40.2:+:19.3 
Range (yrs) 7.8-75 6.9-75.6 
Donor age<50 117 (66.9) 114 (65.1) 
Donor age>50 58 (33.1) 61 (34.9) 
CIT (hrs) 12:+:4 12:+:4 
Blood group 
A 6S (3S.9) SI (46.3) 
B 29 (16.6) 15 (S.6) 
AB 16 (9.2) 15 (8.6) 
0 62 (35.4) 69 (39.4) 
CMV( + )(donor)/( - )(recip) 39 (22.3) 39 (22.3) 
Cytotoxic crossmatch 16 (9.1) 20 (11.4) 
TABLE 2. Indications for Liver Transplantation 
Group 
Diagnosis 
Double n(%) Triple n(%) 
HCV 51 (29.1) 44 (25.1) 
PNCE 35 (20.0) 35 (20.0) 
Cryptogenic 30 (17.1) 20 (11.4) 
PSC 17 (9.7) 14 (8.0) 
PBC 10 (5.7) 20 (11.4) 
Metabolic 8 (4.6) 11 (6.2) 
(AlA) 6 7 
(Wilson's disease) 1 3 
(Hemochromotosis) 1 1 
HBV 6 (3.4) 9 (5.1) 
AIH 6 (3.4) 13 (7.4) 
Benign tumour 4 (2.3) 
Primary liver malignancy 4 (2.3) 2 (1.2) 
Fulminant failure 3 (1. 7) 5 (2.9) 
Other 1 (0.6) 2 (1.2) 
HCV, hepatitis C virus; PNCE, Alcoholic cirrhosis; PSC, primary 
sclerosing cholangitis; PBC, primary biliary cirrhosis; HBV, hepati-
tis B virus; AIH, Auto immune hepatitis; AlA, alpha 1 antitrypsin 
deficiency 
augmented steroids were considered to have steroid-resistant rejec-
tion and were treated with 5 mg OKT3 (Ortho Biotech, Raritan, NJ) 
for 5 to 10 days. Patients who were randomized to TAC, steroids, and 
MMF (T) also received 1 g MMF orally twice a day through nasogas-
tric tube from the day of transplantation and then orally. The pro-
tocol allowed reduction or discontinuation of MMF if there were any 
side effects ascribed to MMF or if the clinical course of the patient 
made it necessary to do so. In addition, patients randomized to D 
could receive MMF to control acute rejection or TAC-related toxicity. 
Criteria used for the pathologic diagnosis of acute hepatic rejection 
were as described in an international consensus document (12). All 
biopsy-proven or clinically suspected rejection episodes that required 
treatment were considered to be rejection for purposes of determin-
ing incidence of rejection. A small proportion of biopsies that were 
graded as borderline to mild and not considered as clinically signif-
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icant (and thus not treated) was not considered to represent a rejec-
tion episode. 
Statistical Analysis 
Patient and graft survival rates were calculated using the Kaplan· 
Meier method and compared by the log-rank test. Differences be-
tween means were tested by the standard two-sample t-test, whereas 
differences in proportions were tested by the Pearson chi-square test. 
Analyses were performed by intention-to-treat analysis. A P-value 
<0.05, was considered statistically significant. Continuous data are 
presented as mean ± standard deviation (mean ± SD) and categor-
ical data are presented as proportions. 
RESULTS 
Patient Survival 
There were no differences in patient survival or graft sur-
vival between the two groups, as shown in Figure 1. The 
I-year actual patient survival was 85.1% and actuarial sur-
vival for 2, 3, and 4 years was 81.6%, 78.6%, and 75.8%, 
respectively, for D, and 87.4%, 85.4%, 81.3%, and 79.9%, 
respectively, for T. The causes of death in both groups are 
shown in Table 3. As expected, infection remained the most 
common cause of death in both groups. 
Retransplantation 
Twenty patients (11.4%) in the double- and 21 (12%) in 
triple-drug regimen required retransplantation (Table 4). 
The most common cause of the need for retransplantation 
was primary nonfunction and hepatic artery thrombosis. The 
mean time to retransplantation was 6.4±10.3 months (range 
0.03-26.8) from the first transplant in group D and 5.9±11.2 
months (range 0.03-42.6) in group T. The overall graft sur-
vival for group D was 77%, 73.4%, 71.2%, and 70% for 1 to 4 
years respectively and 82.3%, 78.2%, 75.1%, and 72.1%, re-
spectively, for group T. 
Cross-over 
During the follow-up period, 38 patients (18.3%) who were 
randomized to the two-drug regimen received MMF to con-
trol ongoing rejection (n=23; 13.1%), nephrotoxicity (n=5; 
2.8%), nephrotoxicity plus rejection (n=5; 2.8%), neurotoxic-
ity (n=3; 1.7%), neurotoxicity plus rejection (n=l, 0.6%) and 
neurotoxicity plus nephrotoxicity plus rejection (n=l, 0.6%). 
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FIGURE 1. Overall patient survival (left) and graft survival 
(right) for both double and triple groups. 
TABLE 3. Causes of death 
Group 
Diagnosis 
Double In(%)] Triple [n(%)] 
Sepsis & MSOF 19 (10.8) 16 (9.2) 
Intracranial 4 (2.2) 4 (2.3) 
Cardiopulmonary 3 (1.7) 3 (1.7) 
Malignancy 5 (2.8) 4 (2.3) 
Pulmonary embolism 20.4) 0(0) 
Respiratory 1 (0.6) 2 (1.2) 
Gastrointestinal 1 (0.6) 0(0) 
Recurrent HCV 1 (0.6) 0(0) 
PTLD 1 (0.6) 0(0) 
Portal vein thrombosis 1 (0.6) 0(0) 
Hepatic necrosis 0(0) 1 (0.6) 
Suicide 0(0) 1 (0.6) 
Anemia, hemorrhage 0(0) 1 (0.6) 
(Jehova's witness) 
Total 38 (21.7) 32 (18.3) 
MSOF, Multisystem organ failure; PTLD, Post transplant lym-
phoproliferative disorder; HCV, hepatitis C virus 
TABLE 4. Causes of retransplantationa 
Causes 
Primary nonfunction 
Hepatic artery thrombosis 
Hepatitis recurrence 
Graft vs. host disease 




















a First retransplantation only, two patients in each group received 
second retransplantation. 
46.4±72.1 days (median 17: range 1-385). One hundred 
three patients (58.9%) who were randomized to T discontin-
ued MMF. Of these 103 patients, 47 (45.6%) discontinued 
within the first month, 76 (73.7%) by 6 months, and 92 
(89.3%) by 1 year. The mean time to discontinuation ofMMF 
was 68.7±87.7 days (median 34: range 1-434) from the time 
of transplantation. The various causes for discontinuation of 
MMF are shown in Table 5. MMF was not necessarily con-
sidered to be the direct cause of adverse events, but antici-
pation or realization of significant complications in the clin-
ical course contributed to the discontinuation of MMF in 
TABLE 5. Reason to discontinue MMF 
Infection 36(20.6%) Gastrointestinal 29(16.6%) 
Sepsis 17 Diarrhea 17 
Cytomegaloviral 10 Nausea, vomiting, abdominal 8 
infection pain 
Recurrent HCV 4 Failure to thrive 3 
Fungal 3 Paralytic ileus 1 
Herpes 1 Miscellaneous 7(4.0%) 
Cryptococcus 1 Primary nonfunction 2 
Hematological 31(17.7%) Postretransplantation 1 
Leukopenia 15 Rash 1 
Anemia 13 Neurological 1 
Thrombocytopenia 3 Cardiac 1 
Recurrent myeloma 1 
Total 103(58.9%) 
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many of these discontinuations. The most common reason to 
discontinue MMF was infection in the face of normal liver 
function and absence of any rejection. 
Rate of Rejection and Treatment of Rejection 
The rate of rejection and the treatment used to control 
rejection were catalogued and then divided into time inter-
vals of <3 months, >3 to <12 months, >12 to <24 months, 
and >24 months after L Tx for all patients. Freedom from 
rejection is shown in Figure 2. As shown in Table 6, the 
overall rate of rejection was not different between the D 
(45.2%) and T (38.9%) groups (P=0.23). However, the rate of 
rejection in the first 3 months was significantly lower for the 
T group (28%) than the D group (38.9%) (P=0.03). Thus the 
rate of rejection for the T group was higher (9.1%) in the 
interval between 3 and 12 months than it was for the D group 
(5.1 %), but this did not reach statistical significance (P=O.2). 
The median time to the first episode of rejection from liver 
transplantation was longer for the T group (24 days), than for 
the D group (14 days) (P=0.08). Of the 79 patients (45.2%) in 
the D group who experienced rejection, 16 had two episodes, 
4 had three episodes, 6 had four episodes of rejection. Simi-
larly, of the 68 patients (38.9%) in the triple group who had 
rejection, 15 had two episodes, 6 had three episodes, and 4 
had four episodes. 
The cumulative episodes of rejection were 121 (0.69 epi-
sodes per patient) in group D versus 108 (0.61 episodes per 
patient) in group T. One hundred eleven (91.7%) in the D 
group and 101 (94.3%) in the T group were biopsy~prov~n 
rejection and the rest were clinical rejections. Ten ?atIents.m 
the D group and five in the T group had borderlme-to-mlld 
rejections on liver biopsy but were not treated and therefore 
are not included in the overall rate of rejection. 
Treatment of Rejection 
Seven patients (4%) in the D group and three patients 
(2.8%) in the T group required OKT3 antibody. The other 
rejections were treated with 1 g methylprednisolone (n=51 
for D, and n=40 for T) or 1 g methylprednisolone and 600 mg 
of steroid taper over the next 5 days (n=63 for D, n=62 for T). 
Two patients in the T group were treated with oral pred-
nisone only (Table 6). 
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FIGURE 2. Rate of freedom from rejection in both groups. 
Baseline Maintenance Immunosuppression 
The baseline mean maintenance dose of TAC and trough 
TAC concentration were comparable in both groups (Table 7). 
The mean prednisone dose was 3.6% to 12% lower for the T 
group during the follow-up period. Freedom from prednisone 
was slightly higher in the T group (68.6%) at 2 years than in 
the D group (60.6%), but this did not reach statistical 
significance. 
Rate of Infection 
The rate of bacterial infection (positive blood culture) was 
35.4% (n=62) in the D and 32% (n=56) in the T group. 
Similarly, 24% (n=42) of patients in the D group and 22.2% 
(n=39) in the T group received gancyclovir either to treat 
cytomegalovirus infection or as preemptive treatment based 
on pp65 surveillance (13,14). In addition, 12 patients (6.9%) 
in the D group and 6 (3.4%) in the T group had an invasive 
fungal infection (Table 8). 
Renal Function 
The mean serum creatinine and blood urea nitrogen at the 
time ofLTx was 1.0±0.8 mg/dl and 19.7±12.8 mg/dl, respec-
tively, in the D group and 1.1±0.9 mg/dl and 18±12 mg/d~I 
respectively, in the T group. The mean rise in serum creatI-
nine and blood urea nitrogen after L Tx was slightly lower in 
the T group than in the D group. Two patients in the group D 
and six patients in the T group were on hemodialysis prior to 
LTx. Thirty-nine patients (22.7%) in the D group who were 
not on dialysis before transplantation required dialysis after 
LTx, and 20 patients (11.4%) in the T group who were not on 
dialysis prior to transplantation required dialysis after L Tx 
(P=0.007). At the last follow-up, 11 patients (6.2%) in the D 
group and 12 patients (6.8%) in the T group were on dialysi~K 
One ofthe patients in the T group suffers from hyperoxalosIs 
type 1. The mean serum creatinine and blood urea nitrogen 
are shown in Table 9 for various time points post-LTx. 
Liver Function 
Liver biochemical function were the same in both groups; 
the mean values are shown in Table 9. 
Hematology 
The rate of anemia (hematocrit<25), leukopenia (white 
blood cell <4,000/ml), and thrombocytopenia (plate-
lets<50 OOO/m}) before LTx and at various times after LTx 
are sho~n in Table 9. The incidence of anemia was 10.7% in 
group D and 10.1% in group T before LTx. Leukopenia ~as 
observed in 29.5% of patients in group D and 26.8% ofpabent 
in group T pre-LTx. Leukopenia improved in both grou~s 
post-LTx; however, the improvement was ~ess not~ble m 
group T than in group D (17.8% in T vs. 9.9% m D) durmg the 
first 6 months. Interestingly, the white blood cell counts 
became comparable after 6 months, presumably because 
MMF was discontinued in nearly 45% of patients by this 
time. Thrombocytopenia existed pre-LTx in 32.2% of group D 
and 31.5% of group T (Table 9). 
DISCUSSION 
Several reports have been published on the utility of add-
ing MMF to a CsA or TAC immunosuppressive regimen in 
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TABLE 6. Rate of rejection and treatment of rejection 
--------------------------
Months post-LTx <3 >3<12 >12<24 >24 Total 
No. of rejection episodes Group n(%) n n n n(%) 
0 D 107 (61.1)* 98 96 96 96 (54.8)*** 
T 126 (72)* 110 108 107 107 (61.1)*** 
1 D 68 (38.9)* 9 2 0 79 (45.2)*** 
T 49 (28)* 16 2 1 68 (38.9)*** 
2 D 14 10 1 1 26 
T 18 6 1 0 25 
3 D 4 5 1 0 10 
T 1 9 0 0 10 
4 D 2 2 2 0 6 
T 2 2 0 0 4 
Total n (% of total rejection episodes) D 88 (72.2) 26 (21.5)** 6 (5.0) 1 (0.8) 121 
T 70 (65.4) 33 (30.8)** 3 (2.8) 1 (0.8) 107 
Mean rejection per patient D 0.69 P=0.69 
T 0.61 
Mean/median interval to first rejection D 53±103/14 P=0.08 
episodes days 
T 83±129/24 
* =p value 0.03, ** =p value 0.32, *** p value 0.23 
TABLE 7. Immunosuppression 
Months post-LTx 
Group 
Mean Tac Dose mg/d 
Mean Tac level ng/ml 
Mean Prednisone dose mg/d 
Percentage difference in Prednisone dose between D and T groups 
Percentage patients off steroid 
































a treatment for cytomegalovirus disease or preemptive based on 
PP65 ref. 13, 14. 
LTx, primarily in the setting of treatment for steroid-resis-
tant rejection or to improve renal function by reducing the 
dose of calcineurin inhibitor (15-20). However, the utility and 
safety of MMF in conjunction with either CsA or TAC as 
primary immunosuppressive therapy in LTx has not been 
previously established. This is the largest reported prospec-
tive trial using TAC and MMF in LTx, with a mean follow-up 
of nearly 3 years. 
There have been other prospective, randomized trials study-
ing the use ofMMF with TAC or CsA in primary LTx. Klupp et 
1 3 6 12 24 
D 8.6 8.3 7.2 4.9 3.4 
T 8.2 8.3 7.2 5.6 4.6 
D 12 11 10.1 7.1 8.1 
T 11.2 10.3 9.8 8.7 9.2 
D 10.1 7.9 5.6 3.7 2.5 
T 9.1 7.5 5.4 3.5 2.2 
9.9 5.1 3.6 5.4 12 
D 1.8 12 20.2 36.9 60 
T 1.2 12.7 30.5 47.5 68.6 
al reported a series of 120 cases (randomized in three groups) 
comparing Neoral, steroids + MMF (grm.mI) to TAC, steroids 
+ MMF (groupIl) to TAC and steroids alone (grouplll) (21). 
They did not find any benefit in terms of patient survival, graft 
survival or rate of rejection with use of MMF with TAC com-
pared (groupII) to TAC alone (groupIII). However, when com-
pared to a Neoral and MMF combination (grm.mI), patient 
survival in both TAC groups (II and III) were numerically 
greater and the graft survival was significantly higher with 
TAC (groupll and III vis group I), while the corresponding 
rate of rejection was significantly lower (groupll and III vIs 
group I). The rate of discontinuation ofMMF in either the TAC 
or esA groups was 58%. In addition, there was a tendency to 
higher cytomegalovirus and fungal infections in both MMF 
groups. Therefore, they concluded that there was no added 
benefit of adding MMF to a TAC-based immunosuppressive 
regimen in primary LTx. In the pivotal randomized, multi-
center trial (3), consisting of 565 patients, Neoral, steroids, plus 
AZA (n=287) was compared with Neoral, steroids, plus MMF 
(n=278) in primary LTx. MMF was given i.v. initially, and 
doses were adjusted to obtain a similar area under the curve as 
was obtained for renal recipients receiving MMF 1 g twice a 
day. The withdrawal rate ofMMF was 45.3% and that of AZA 
was 44% in this trial. Rates of rejection were 38.1% and 47.7%, 
respectively (P<O.02); however, the follow-up was less than 1 
year post-LTx. 
---- - K----~---~--IKI-
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TABLE 9. Biochemical and hematological values hematological function 
Months Post L Tx Group 0 3 6 12 24 
Group 
Liver Function 
T. Bilirubi mgldl D 7.4::!::6.2 0.8::!:: 1.8 0.5::!::1.1 0.3::!::0.4 0.2::!::0.4 
T 7.1::!::5.3 0.7::!::1.8 0.5::!::1.5 0.6::!::2.8 0.1::!::0.3 
AST uJl D 1519::!::1687 33.4::!::41.2 24.3::!::35 21.6::!::41.4 17.2::!::37.9 
T 1311::!::1434 32::!::37.8 25::!::40 36.5::!::57.6 14.6::!::55 
ALTuJl D 673::!::807 49::!::72.2 38::!::64 28.4::!::55 20.5::!::45.1 
T 63 l::!:: 750 48::!::66.4 35.4::!::57.6 41.8::!::78 16.4::!::44 
Alk P04 uJl D 74::!::105 80.2::!::204 39::!::106 22. I::!:: 55 22::!::67 
T 115::!::172 57::!:: 102.1 43::!::191.2 33.2::!::120 19.7::!::58 
GGTP uJl D 103::!::151 179::!::361.7 142.4::!::435 90.9::!::251 59::!:: 157 
T 101::!::230 157::!::407.5 114::!::284 88.7::!::203 31.6::!::94 
Renal Function 
BUN D 19.7::!::12.8 28::!::15.7 28.3::!::13.8 24.9::!::10.6 25::!::11 
T 18::!::12 25::!::11 26::!::11 24::!::11 24::!::11 
Creat D 1.0::!::0.8 1.3::!::0.6 1.3::!::0.6 1.3::!::0.3 1.6::!:: 1.5 
T 1. l::!:: 0.9 1.3::!::0.9 1.4::!:: 1.1 1.3::!::0.6 1.6::!:: 1.4 
Hematology 
Hematocrit % D 32::!::5 35::!::5 35::!::6 37::!::4 37::!::4 
T 32::!::5 34::!::5· 35::!::4 36::!::5 35::!::5 
Platelates kldl D 76::!::48 171::!::89 166::!::94 160::!::81 170::!::89 
T 81::!::63 170::!:: 102 159::!::62 151::!::70 155::!::84 
Leukocyte kldl D 7.1::!::4 
T 7.0::!::4 
Hematological disorders 
Leukopenia D 29.5 
(WBC<4.0klml) T 26.8 
Anemia D 10.7 
(HCT<25%) T 10.1 
Thrombocytopenia D 32.2 
(Platlets<50klml) T 31.5 
Our report noted similar patient survival and graft sur-
vival post-LTx regardless of whether MMF was included in 
the immunosuppressive regimen used. Although the initial 
rate of rejection was significantly lower in the group of pa-
tients randomized to MMF, this rate increased during the 
remainder of the year as MMF was discontinued. This lim-
ited the overall advantage ofMMF from the rejection stand-
point. The use of MMF appeared to be associated with an 
advantage in terms of reduced renal toxicity in the early 
post-LTx period. The need for new-onset dialysis post-LTx 
was 11.4% with MMF versus 22.7% in patients who did not 
receive MMF, although the renal function at 1 year was not 
different. 
The addition of MMF did not appear to increase the risk of 
infectious complications, because the rate of bacterial, viral, 
or fungal infection was not higher with use of MMF than 
without MMF (22). However, the high withdrawal rate of 
MMF in this study reflects the inherently high incidence of 
infectious complications in LTx patients, regardless of their 
induction or baseline immunosuppressive regimen. The lim-
itation of antiproliferative agents such as MMF is the preex-
isting leukopenia, thrombocytopenia, and hypersplenism in 
the majority of L Tx candidates. Our study noted that, in 
almost half of the patients after primary LTx, the clinicians 
elected to discontinue MMF because of infectious events, 
depressed hematological counts, and gastrointestinal com-
plaints. Similar findings have been reported in a European 
multicenter trial ofTAC, steroids, plus AZA versus TAC and 
steroids (23). In this study, almost half of the patients ran-
7::!::3 5.8::!::2.5 6::!::2.4 7.3::!::7.8 
6::!::4 5.8::!::2 5.6::!::2 5. 6::!:: 2.4 
9.9 18.8 18.1 17.6 
17.8 15.3 19.3 21.2 
2.2 1.9 1.2 1.6 
4.2 0 1 2 
2.2 1.9 2.5 5 
1.4 1.9 2 6.2 
domized to the T group were taken off AZA by 1 year post-
LTx. Although some of these interpretational issues would 
have been easily addressed by the addition of a placebo to the 
non-MMF group (thus blinding the clinicians involved in the 
management of these complex patients), this was not deemed 
to be of priority by the manufacturer ofMMF. These factors 
that limit the ability to use MMF are not usually seen in 
kidney transplant patients and explain the differences in 
dropout rates. Fisher et al. reported in their randomized trial 
of MMF with Neoral versus TAC, that gastrointestinal tox-
icity and bone marrow suppression were not notable, al-
though the study was limited to a 6-month follow-up, and 
target dose of MMF at 6 month was 1 g/day (24). 
This study was not designed to evaluate steroid with-
drawal after L Tx, although there appeared to be a slightly 
higher number of patients in the MMF group that were 
steroid free. However, the mean dose of corticosteroids was 
4% to 12% lower with use of MMF. Stegall et al. have (15) 
reported a greater ability to wean patients from corticoste-
roids at 14 days post-LTx with a modest rejection rate, ap-
proximately 40%. A kidney transplant trial designed to as-
sess the ability of the addition of MMF to a Neoral and 
corticosteroid immunosuppressive regimen resulted in satis-
factorily low rates of rejection-free maintenance but did not 
allow corticosteroid withdrawal without a significantly 
higher incidence of rejection (25). 
Although this study, like others that have utilized MMF in 
LTx, has not clearly demonstrated a role of MMF as a pri-
mary immunosuppressant, MMF has a role in the treatment 
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of steroid-resistant rejection in patients experiencing neph-
rotoxicity or neurotoxicity due to calcineurin inhibitors or for 
its steroid-sparing effects following L Tx. MMF treatment 
may also be useful for other immunosuppressive drug com-
plications, such as new-onset insulin-dependant diabetes 
mellitus, hypertension, or osteoporosis. However, it remains 
to be defined which population of LTx patients and under 
which conditions will benefit from MMF (26). 
CONCLUSIONS 
The use of MMF in an immunosuppressive regimen for 
LTx patients is not associated with differences in patient or 
graft survival. There is less rejection, improved early renal 
function, and the need for less corticosteroids with the use of 
MMF in a TAC-based regimen; however, several factors in-
herent in the LTx procedure, leading MMF discontinuation 
in a significant proportion of patients, limit its general use 
and maximal potential. MMF may be best suited for selected 
patients who develop rejection, nephrotoxicity, and neurotox-
icity or in whom aggressive steroid weaning is desirable after 
LTx. 
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